COVID-19: Japanese corona drug: S-217622 clinical trial started
-Shionogi S-217622 clinical trial started, can be administered at home-
Shionogi:
On July 26, it announced that it had started a clinical trial of the new coronavirus drug candidate S-217622 in Japan.
It is administered in the early stages of infection with the aim of suppressing aggravation and improving symptoms such as fever and cough.
New Corona Drinking Medicine S-217622:
Currently, the only treatment approved in Japan for mildly ill patients is intravenous drip.
If easy-to-take medicines are put into practical use, the tight medical system can be avoided.
Therapeutic drug candidate S-217622
Suppresses “the action of enzymes required for virus growth”.
Suppose “how to use once a day for several days”.
Safety verification:
The first phase of the clinical trial started on July 22nd.
It will be administered to 75 healthy adults aged 20 to 55 years to verify its safety.
The schedule for clinical trials and approval applications after the second stage is undecided.
Japanese therapeutic drug candidates:
There are currently four new corona treatments approved in Japan.
Intravenous drip for mildly ill people:
Chugai’s “antibody cocktail therapy” is the only drug for mildly ill patients.
Two types of antibodies are administered by intravenous drip and are targeted only to inpatients.
Drugs for mildly ill people:
Major pharmaceutical companies in Japan and overseas are developing medicines for the treatment of corona in mildly ill patients.
“AT-527”
Drug candidate “AT-527” that Chugai obtained development and marketing rights from Roche
It is in the final stage of clinical trials in Japan and is aiming for early commercialization.
“Mornupiravir”
In June, Merck’s Japanese subsidiary MSD launched “Mornupiravir”, a drug for mildly ill patients in Japan.
We have entered the final stage of clinical trials.
Administer twice daily for 5 days to outpatients with early symptoms.
“Avigan”
FUJIFILM Holdings’ antiviral drug “Avigan”
Nihon Keizai Shimbun
https://www.nikkei.com/article/DGXZQOUF260WV0W1A720C2000000/